Turning the Tide Against Cancer Through Sustained Medical Innovation

Guest Blog Contributors
Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
Margaret Foti, Ph.D., M.D. (h.c.), Chief Executive Officer, American Association for Cancer Research
Marcia A. Kean, M.B.A., Chairman, Feinstein Kean Healthcare

Turning the Tide Banner

We live in extraordinary times. Over the past decade, advances in science and medicine have transformed our approach to fighting cancer. In many cases, a cancer diagnosis is no longer a death sentence, but rather a chronic condition managed through new therapies. Personalized medicines have moved us away from one-size-fits-all, trial-and-error treatment options to more patient-centered cancer research and care. As we continue to learn more about the molecular underpinnings leading to the more than 200 diseases that comprise cancer, we will be able to more effectively prevent, detect, diagnose, and treat these diseases.

But we also live in a time of great economic pressure, where healthcare costs have reached unsustainable levels and our current cost-constrained environment threatens future innovation and our ability to deliver patient-centered cancer care. In 2011, the Personalized Medicine Coalition, American Association for Cancer Research, and Feinstein Kean Healthcare came together to address the challenge of sustaining progress against cancer while facing the economic imperative to reduce healthcare spending. Since the beginnings of the Turning the Tide Against Cancer initiative, we have seen a groundswell of support from across the cancer community for a shift to a more patient-centric, high-value system of cancer research and care. To do so, we must put the right policies in place that will incentivize scientific discovery and medical progress, while addressing rising healthcare costs.

On October 9, we will convene the second Turning the Tide Against Cancer Through Sustained Medical Innovation national conference to hear from the cancer and health policy communities to further define and address these issues, and refine our recommendations to policymakers.

If we are to continue to realize the extraordinary promise of scientific discovery and personalized cancer medicine, we must advance policies that support a more efficient and effective healthcare system. We hope that this conference provides the platform for examining innovative approaches to conducting personalized, patient-centered cancer research; optimizing the processes through which new medical products are evaluated and approved; and implementing care delivery and payment models that deliver high-value, affordable cancer care to patients.

We invite you to join us for the conference on October 9 in Washington, D.C. or online via webcast and #T3Cancer, and to join us in ongoing collaboration so that together, we can advocate for the policy changes that will result in patient-centric, high-value cancer research and care.

Watch these two-minute videos to learn more about:

The Melanoma Research Alliance (MRA) is proud to sponsor and support the Turning the Tide Against Cancer initiative.  As a contributor to the initiative’s expert working group, MRA’s president and CEO Wendy Selig joined fellow experts in oncology, patient advocacy, and health policy to identify and refine specific policy options that can move us toward a more patient-centric, high-value system of cancer research and care.  Through collaboration with all invested stakeholders, we are working to accelerate the pace of scientific discovery and galvanize the field of cancer treatment to benefit all patients.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s